Inagene launches GLP-1 Insights Program combining genetic insights with registered dietitian support to help Canadians understand their genetic response to weight management and diabetes medications

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Inagene launches GLP-1 Insights Program combining genetic insights with registered dietitian support to help Canadians understand their genetic response to weight management and diabetes medicationsAuthor of the article:New research suggest genetics may help explain why individual response to weight management and diabetes medications can varyTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Inagene Diagnostics has launched a new product giving Canadians access to emerging research on how genetics may influence response to GLP-1 medications.Medications such as Ozempic, Wegovy, Mounjaro and Zepbound have transformed weight management and diabetes care, but individual responses vary widely – some people see strong results while others experience less benefit. Additionally, tolerance of treatment side effects can be highly variable. Inagene’s new GLP-1 Insights Program provides personalized genetic insights into GLP-1 medications, along with individual dietitian support to help people reach their health goals.Research suggests that approximately 3 million adults in Canada currently take a GLP-1 medication, while more than 2 million are estimated to be interested in pursuing treatment.¹ Most people who start taking GLP-1 medications are estimated to be off them within a year,² with side effects reported to be a major barrier.²˒³Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“GLP-1 medications are often talked about as though everyone should respond to them in much the same way. But people are different, and their experiences and side effects can be different too,” said Peter Lowas, CEO at Inagene. “Genetics is one piece of that picture. Our goal is to give people another source of useful information as they work with their healthcare provider to better manage their side effects.”Alongside genetic insights, the GLP-1 Insights Program includes three sessions with a registered dietitian to provide personalized support to help individuals make sustainable dietary changes and feel more confident as they adapt to their treatment.“Our goal is to give people information they can bring to the conversation with their healthcare provider,” said Ben Pinder, Global Scientific Director at Inagene. “Genetic insights don’t replace clinical expertise, but they can provide additional context about why people can differ in their response to medications including research examining genetic differences associated with certain side effects.”Inagene’s GLP-1 Insights Program combines a simple thirty-second at-home cheek swab with three personalized sessions with a registered dietitian. By testing five genes, the program provides easy-to-understand insights into how an individual’s genetics may influence their response to certain medications. New research has linked certain genetic variants to improved response to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), as well as differences in the likelihood of experiencing side effects such as severe nausea or vomiting. The Inagene GLP-1 Insights Program also reports variants that research has associated with differences in response to certain diabetes medications.For more information about Inagene’s GLP-1 Insights Program, please visit Inagene.com/pages/lp-glp-1.About InageneInagene is a Canadian company headquartered in Toronto, Ontario. Its goal is to be a trusted ally working to shorten the journey to optimal health. Inagene delivers personalized health insights tailored to each person’s genetic profile, helping people make more informed decisions about medications. Genetic analysis is performed in Inagene’s CLIA-accredited Toronto laboratory. Inagene also holds a Medical Device Establishment Licence from Health Canada.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.1: Leger. GLP-1 Usage in Canada and the US. OMNI Report. Published 2026 Mar 3.2: Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. Published 2025 Jan 2. doi:10.1001/jamanetworkopen.2024.573493: Ceriello A, Prattichizzo F, Mastan Sheik Abdullah AR, et al. Causes and consequences of discontinuation of GLP1RAs or tirzepatide. Nat Rev Endocrinol. 2026;22(9):530-542. doi:10.1038/s41574-026-01258-5Media ContactRose-Marie MénardPilot PMR+1-579-622-9925rosemarie.menard@pilotpmr.com Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.